Enforcement Report - Week of June 7, 2023
HAYWARD, Calif., March 14, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora). The agreement allows AcelRx to participate in the long-term value expected to be created by Alora as they expand the commercialization of DSUVIA.
AcelRx Pharma Announces Abstract Acceptance at the ANESTHESIOLOGY 2022
HAYWARD, Calif., May 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of clinical data from an investigator-initiated trial in patients undergoing lengthy plastic surgery procedures performed under general anesthesia, where use of a single sufentanil sublingual tablet 30 mcg (SST; DSUVIA®) in conjunction with intravenous (IV) opioids was able to dramatically reduce postoperative opioid requirements compared to an equivalent dose of opioids administered only via the IV route.
HAYWARD, Calif., Jan. 12, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of an editorial regarding the use of sufentanil sublingual tablet (SST; DSUVIA®) in total joint replacement surgery by Dr. Scott Sigman in the Journal of Orthopaedic Experience and Innovation. Dr. Sigman is a board-certified orthopedic surgeon at Orthopedic Surgical Associates of Lowell, the former Chief of Orthopedics at Lowell General Hospital in Lowell Massachusetts, and an internationally recognized leader in opioid-sparing orthopedic surgery.
HAYWARD, Calif., Aug. 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation on the effects of administering sufentanil sublingual tablet 30 mcg (SST) at Miami Cosmetic Surgery held at the Miami Beach Convention Center in Miami Beach, Florida from August 25-27, 2021.
The FDA promo police aren't done with opioid marketers yet. And the Office of Prescription Drug Promotion's (OPDP's) first warning letter of 2021 is notable even among the rapping fentanyl pill bottle promotions of yore.
FDA issues warning to AcelRx for making false and misleading claims about the risks and benefits of Dsuvia